Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma
Sponsor: National Cancer Institute (NCI)
Terminated
Change in standard of care
Other terminated trials from National Cancer Institute (NCI)
A PHASE2 clinical study on Recurrent Melanoma and Stage IV Skin Melanoma, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 11 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Completed → Terminated
▶ Show 6 earlier versions
-
Nov 2019 — Mar 2020 [monthly]
Completed PHASE2
-
Mar 2019 — Nov 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .